Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells
Authors:
- 1 May 2008
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 32 (5) , 771-780
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinomaCancer, 2007
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Valproic Acid–Induced Gene Expression through Production of Reactive Oxygen SpeciesCancer Research, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic MalignanciesJournal of Clinical Oncology, 2005
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005
- Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogueCancer Biology & Therapy, 2004
- Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase InhibitorsClinical Cancer Research, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004